Biodexa Pharmaceuticals (BDRX) Asset Writedowns and Impairment (2020)
Biodexa Pharmaceuticals (BDRX) reported Asset Writedowns and Impairment of $15.3 million for Q4 2020, up 4.86% sequentially from $14.6 million in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Asset Writedowns and Impairment (2020) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $15.3 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 15.31 Mn |
| Dec 31, 2020 | 15.31 Mn |
| Sep 10, 2020 | 14.60 Mn |
| Sep 10, 2020 | 14.60 Mn |